27 June 2024
PureTech Health plc
PDMR Notifications
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases, announces the sale of certain shares by members of executive management and non-executive directors ("PDMRs") pursuant to its recently completed Tender Offer.
The Company's total issued ordinary share capital is 257,927,489 shares, 18,608,909 shares of which are held in treasury by the Company.
PDMR Notification
The information contained in the below notification is disclosed in accordance with Article 19 of the EU Market Abuse Regulation.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||||||||||
| a) | Name | Eric Elenko John LaMattina Robert Langer
| ||||||||||||
| 2 | Reason for the notification | |||||||||||||
| a) | Position/status | Eric Elenko: PresidentJohn LaMattina: Non-Executive DirectorRobert Langer: Non-Executive Director | ||||||||||||
| b) | Initial notification/Amendment | Initial Notification | ||||||||||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||
| a) | Name | PureTech Health plc | ||||||||||||
| b) | LEI | 213800LVPDNO2Z9T9I39 | ||||||||||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||||||
| a) | Description of the financial instrument, type of instrument |
| ||||||||||||
| b) | Nature of the transaction | Sale of ordinary shares pursuant to Company's recently completed Tender Offer. | ||||||||||||
| c) | Price(s) and volume(s) |
| ||||||||||||
| e) | Date of the transaction | 24 June 2024 | ||||||||||||
| f) | Place of the transaction | London Stock Exchange (XLON) | ||||||||||||
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.
For more information, visit www.puretechhealth.com or connect with us on X (formerly Twitter) @puretechh.
Contact:
PureTech
Investor Relations
IR@puretechhealth.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.